Sectra to Acquire Oxipit to Strengthen Autonomous AI in Radiology

March 12, 2026
Sectra has agreed to acquire Lithuanian radiology AI company Oxipit, known for its CE Class IIb-certified autonomous chest X-ray solution, ChestLink. The deal is expected to close in March 2026 and will see Oxipit operate as Sectra’s dedicated AI development center.

Sectra has entered into an agreement to acquire Oxipit, a Lithuanian company specializing in AI-based radiology solutions, announced in a press release. The transaction is expected to close in March 2026, pending customary conditions.

Oxipit developed ChestLink, an autonomous AI system certified under CE Class IIb regulations for chest X-ray analysis. The software automatically identifies and clears high-confidence normal exams from radiologists’ worklists, allowing them to focus on more complex cases. It is already available through Sectra’s Amplifier Marketplace for AI.

Following the acquisition, Oxipit will operate as a dedicated AI development center within Sectra’s Imaging IT Solutions division. The integration will maintain Sectra’s vendor-neutral Amplifier ecosystem, giving healthcare providers access to a range of vetted AI tools. The deal is financed with Sectra’s own funds, including an upfront payment and contingent consideration linked to future milestones. Financial terms were not disclosed.

We hope you enjoyed this article.

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more